KEI Comments on Exclusive License to Stage One Immunotherapeutics

On October 20, 2025, Knowledge Ecology International (KEI) submitted comments to the NIH in response to the Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors” (90 FR 47782) The… Continue Reading

KEI Comments on Exclusive License of Zika Strain to AARI

On October 14, 2025, Knowledge Ecology International (KEI) provided the NIH with comments regarding the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy” (90 FR 46414) to Advocate Aurora Research… Continue Reading

KEI Comments to the NIH on Exclusive License to Lysin Therapeutics

On September 24, 2025, Knowledge Ecology International submitted comments to the NIH regarding the “Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers” (90 FR 43617) to Lysin Therapeutics. Although the… Continue Reading

KEI Submits FOIA Regarding FDA Orphan Products Grant Program

On July 28, 2025, Knowledge Ecology International (KEI) submitted a Freedom of Information Act request for records concerning the Food and Drug Administration (FDA) Orphan Products Grant Program. The program (administered by the FDA’s Office of Orphan Products Development (OOPD))… Continue Reading

KEI Comments on NIH Exclusive License to Neurala for Central Nervous System Disorders

On June 2, 2025, Knowledge Ecology International (KEI) offered comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same”… Continue Reading

KEI Comments on NIH Exclusive License to Sangam Lifesciences for Drug Delivery Platform

On May 7, 2025, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” (90 FR 16878) to… Continue Reading

KEI Submissions to 2025 Special 301 Review

Annually, the Office of the United States Trade Representative spearheads the Special 301 review process, whose goal is to produce a report that names-and-shames countries that have committed perceived offenses against intellectual property rights. The USTR solicits written comments from… Continue Reading

KEI Letter Opposing Diplomatic Conference for WIPO Broadcasting Treaty

Knowledge Ecology International sent a January 13, 2025 letter to the delegates of the World Intellectual Property Organization (WIPO) Standing Committee on Copyright and Related Rights (SCCR) opposing the convening of a diplomatic Conference for a WIPO Treaty for the… Continue Reading

KEI Comments to the NIH on Cancer Treatment License to Straightline Bio

On December 26, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-KK-LC-1 T Cell Receptors for the Treatment of Cancer” (89 FR 99888) to StraightLine… Continue Reading